Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.

12 May 2014

Researchers discover new mechanism that distinguishes normal blood stem cells from blood cancers

Researchers at Dartmouth's Norris Cotton Cancer Center have published results from a study Cell Reports that discovers a new mechanism that distinguishes normal blood stem cells from blood cancers.

9 May 2014

The Leukemia & Lymphoma Society passes $1 billion mark in blood cancer research investment

The Leukemia & Lymphoma Society announced that it has passed the $1 billion mark in research investment, a significant milestone in the cancer research landscape as LLS continues its 65 year pursuit of advancing breakthrough therapies, finding cures and ensuring access to life-saving therapies for all blood cancer patients.

8 May 2014

New technique expands number of functional cord blood stem cells for transplantation

Adults suffering from diseases such as leukemia, lymphoma, and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood (CB) stems cells to generate in greater numbers making them more useful in adult transplantation.

8 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use.

6 May 2014

ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer.

6 May 2014

NCCN publishes new patient resource for stage 0 breast cancer

The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation®, announces the availability of the NCCN Guidelines for Patients: Breast Cancer Stages 0 - IV—the latest addition to the library of NCCN Guidelines for Patients available online free-of-charge at NCCN.org/patients.

6 May 2014

MEI Pharma begins ME-344 Phase Ib clinical study in patients with solid tumors

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers.

6 May 2014

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies.

2 May 2014

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension---a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).

30 Apr 2014

3D shape of leukemia cell's genome holds key to solving puzzle of human diseases

To solve a puzzle, you need to recognize shapes, patterns and a particular kind of order. In much the same way, researchers at McGill University have discovered that the 3D shape of a leukemia cell's genome holds a key to solving the puzzle of human diseases. The researchers report their findings in the open access journal Genome Biology.

30 Apr 2014

Study: Mutations could have major impact on treatment of human blood diseases

A study published today in Nature Genetics has revealed mutations that could have a major impact on the future diagnosis and treatment of many human diseases.

29 Apr 2014

CPX-351 treatment leads to higher chances of remission in AML patients, says study

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

25 Apr 2014

Tolero Pharmaceuticals' Alvocidib gets Orphan Drug Designation for acute myeloid leukemia treatment

Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for Alvocidib for the treatment of patients with acute myeloid leukemia (AML).

23 Apr 2014

Scientists develop DNA nanodevices that survive body's immune defenses

It's a familiar trope in science fiction: In enemy territory, activate your cloaking device. And real-world viruses use similar tactics to make themselves invisible to the immune system.

23 Apr 2014

HOPA Membership Awards winners for 2014 announced at 10th Annual Conference

The Hematology/Oncology Pharmacy Association (HOPA) announced the recipients of the 2014 HOPA Membership Awards at its 10th Annual Conference in March. HOPA Membership Awards recognize members who have shown outstanding achievement in their field.

23 Apr 2014

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra.

22 Apr 2014

Ockham to partner with Leukemia and Lymphoma Society to increase commitment to cancer philanthropy

Ockham Development will partner with the Leukemia and Lymphoma Society of North Carolina chapter during 2014 to increase its commitment to cancer-directed philanthropy and collaborate with the Society to support the company's personal health and fitness goals.

22 Apr 2014

Leukemia News and Research

Further Reading

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

Researchers discover new mechanism that distinguishes normal blood stem cells from blood cancers

The Leukemia & Lymphoma Society passes $1 billion mark in blood cancer research investment

New technique expands number of functional cord blood stem cells for transplantation

ARIAD provides update on corporate developments, reports Q1 2014 financial results

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Teva's SYNRIBO for injection receives FDA approval for home administration

ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

NCCN publishes new patient resource for stage 0 breast cancer

MEI Pharma begins ME-344 Phase Ib clinical study in patients with solid tumors

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

RDT receives FDA approval for new liquid form of treatment for patients with ALL

3D shape of leukemia cell's genome holds key to solving puzzle of human diseases

Study: Mutations could have major impact on treatment of human blood diseases

CPX-351 treatment leads to higher chances of remission in AML patients, says study

Tolero Pharmaceuticals' Alvocidib gets Orphan Drug Designation for acute myeloid leukemia treatment

Scientists develop DNA nanodevices that survive body's immune defenses

HOPA Membership Awards winners for 2014 announced at 10th Annual Conference

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

Ockham to partner with Leukemia and Lymphoma Society to increase commitment to cancer philanthropy

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News